Shimakata el al. observed that Alfa-fetoprotein (AFP)-producing GC expresses both SLC29A1 and SLC22A2 at high levels, thus suggesting that patients with this aggressive subtype of GC could benefit from gemcitabine/5-FU combination therapy [128]. The gene discussed is AFP; the disease is gastric cancer.